Join a study exploring potential treatments
with a new class of investigational medication
Alzheimer's Disease (AD)
Bipolar I or II disorder (BD-I or BD-II)
Alzheimer's Disease (AD)
Alzheimer's Disease (AD)
Migraine Disorder (aged 6-17)
Migraine Disorder (aged 6-17)
Postpartum Depression (PPD)
Migraine (aged 12-17)
Major Depressive Disorder (MDD)
Bipolar I Disorder (BD-I)
Migraine Disorder (aged 6-17)
Covid-19 Vaccine
Generalized Anxiety Disorder (GAD)
Alzheimer's Disease (AD aged 55-90)
Bipolar I or Bipolar II Disorder(BD-I or BD-II)
Autism (ASD aged 13-17)
Bipolar I Disorder (BD-I aged 18-75)
Attention-Deficit/Hyperactivity Disorder (ADHD aged 13-17)
Alzheimer's Disease (AD 55-85)
Attention-Deficit/Hyperactivity Disorder (ADHD aged 4-5)
Bipolar Disorder (aged 13-17)
Schizophrenia (SCZ)
Major Depressive Disorder (MDD aged 18-64)
Schizophrenia (SCZ aged 13-17)